HSK36273

DRUG2 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

HealthyRenal Replacement Therapy

Phase 1

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers

CompletedNCT05742126

Haisco Pharmaceutical Group Co., Ltd.Healthy

Start: 2022-04-11End: 2022-09-15Updated: 2023-02-23

Phase 2

A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects

Haisco Pharmaceutical Group Co., Ltd.Renal Replacement Therapy

Start: 2022-11-30End: 2023-10-31Target: 156Updated: 2022-11-02